MIT spinout Strand Therapeutics has developed a new class of mRNA molecules that can sense where they are in the body, for more targeted and powerful treatments.
An online model enables users to calculate the least-cost strategy for a specific regional grid under various assumptions; outcomes vary widely from region to region.